google1bf7230088a58a15

Tocilizumab and Baricitinib Mechanisms of Action


COVID-19 Pathogenesis: Late COVID-19

In the late stage, pulmonary edema can fill the alveolar spaces with hyaline membrane formation, compatible with early-phase acute respiratory distress syndrome (ARDS).

Joost Wiersinga W. eta al. JAMA Review 2020 doi:10.1001/jama.2020.12839


The Road to COVID-19 EUA Approval

Tocilizumab

  • 1/8/2010 FDA approval for treatment of moderate to severe rheumatoid arthritis
  • 8/31/2017 FDA approval for treatment of CAR T cell-induced cytokine release syndrome
  • 6/24/2021 EUA authorization for COVID-19 hospitalized adults and children

Baricitinib

  • 6/1/2018 FDA approval for treatment of moderate to severe rheumatoid arthritis
  • 11/19/2020 EUA for baricitinib in combination with remdesivir for COVID-19 hospitalized adults and children

Tocilizumab: Key COVID-19 Trials


Baricitinib: Key COVID-19 Trial


Tocilizumab For Treatment of COVD-19

Baricitinib For Treatment of COVD-19


Baricitinib Dose Adjustments Due to Laboratory Abnormalities

FDA Emergency Use Authorization for Baricitinib 11/19/2020

Pin It on Pinterest

google-site-verification: google1bf7230088a58a15.html
%d bloggers like this: